Stanford Medicine researchers have made significant strides in understanding the neurological mechanisms associated with autism spectrum disorder (ASD). Their study, set to be published in Science Advances, centers on the reticular thalamic nucleus, a brain region that regulates sensory information between the thalamus and the cortex.
Utilizing a mouse model genetically modified to simulate autism, the team observed heightened activity in the reticular thalamic nucleus during exposure to stimuli and social interactions. This overactivity was linked to behaviors typical of ASD, such as increased motor activity, reduced social engagement, and susceptibility to seizures. The researchers noted that individuals with autism are disproportionately affected by epilepsy, with a prevalence rate of approximately 30%, compared to 1% in the general population.
To explore potential treatments, the scientists administered drugs that targeted the reticular thalamic nucleus, successfully reversing many autism-like symptoms in the modified mice. One of the experimental drugs tested, Z944, which is also under investigation for epilepsy treatment, appeared effective in alleviating behavioral deficits. Additionally, through a process called DREADD-based neuromodulation, researchers were able to induce and suppress symptoms in normal mice by manipulating the activity of the reticular thalamic nucleus.
John Huguenard, PhD, a professor of neurology, and lead author Sung-Soo Jang, PhD, emphasize the importance of these findings in identifying the reticular thalamic nucleus as a promising target for future therapies aimed at treating autism spectrum disorders. This research not only sheds light on the neural circuits involved in ASD but also suggests potential overlaps with epilepsy, paving the way for integrated treatment approaches.